loading
Sangamo Therapeutics Inc stock is traded at $1.915, with a volume of 733.52K. It is down -2.05% in the last 24 hours and up +109.20% over the past month. Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
733.52K
Relative Volume:
0.10
Market Cap:
$423.50M
Revenue:
$176.23M
Net Income/Loss:
$-257.83M
P/E Ratio:
-1.3207
EPS:
-1.45
Net Cash Flow:
$-246.00M
1W Performance:
-11.16%
1M Performance:
+109.20%
6M Performance:
+219.72%
1Y Performance:
+410.97%
1-Day Range:
Value
$1.89
$1.97
1-Week Range:
Value
$1.82
$2.185
52-Week Range:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
Name
Sangamo Therapeutics Inc
Name
Phone
(510) 970-6000
Name
Address
501 CANAL BLVD., RICHMOND, CA
Name
Employee
405
Name
Twitter
@sangamotx
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
SGMO's Discussions on Twitter

Compare SGMO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
SGMO 1.915 423.50M 176.23M -257.83M -246.00M -1.45
VRTX 447.55 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.92 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.88 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.41 24.49B 3.30B -501.07M 1.03B 11.54

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-28-23 Downgrade BofA Securities Neutral → Underperform
Feb-27-23 Upgrade Wedbush Neutral → Outperform
Jan-06-23 Downgrade BofA Securities Buy → Neutral
Jun-13-22 Resumed Wedbush Neutral
May-04-21 Initiated RBC Capital Mkts Outperform
Jan-07-21 Resumed Guggenheim Neutral
Jan-06-21 Initiated Stifel Hold
Dec-16-20 Resumed H.C. Wainwright Buy
Sep-08-20 Initiated BofA Securities Buy
Jul-07-20 Initiated SunTrust Buy
Aug-26-19 Initiated H.C. Wainwright Buy
Nov-14-18 Downgrade JP Morgan Overweight → Neutral
Nov-09-18 Downgrade Guggenheim Buy → Neutral
Oct-10-18 Initiated Guggenheim Buy
Jun-20-18 Initiated BofA/Merrill Buy
Nov-15-17 Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17 Resumed Jefferies Buy
Nov-01-16 Downgrade Wedbush Outperform → Neutral
Oct-19-16 Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15 Initiated Wells Fargo Outperform
Oct-23-15 Resumed Jefferies Buy
May-03-13 Initiated BioLogic Equity Research Sell
Feb-23-11 Reiterated JMP Securities Mkt Outperform
Jul-29-10 Reiterated Wedbush Outperform
Oct-19-09 Initiated Brean Murray Sell
Oct-07-09 Reiterated Leerink Swann Outperform
Aug-25-09 Reiterated JMP Securities Mkt Outperform
View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

pulisher
Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire

Nov 12, 2024
pulisher
Nov 11, 2024

Sangamo Therapeutics's Earnings Outlook - Benzinga

Nov 11, 2024
pulisher
Nov 08, 2024

FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 07, 2024

Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 06, 2024

Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph

Nov 06, 2024
pulisher
Nov 05, 2024

Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan

Nov 04, 2024
pulisher
Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 29, 2024

Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic

Oct 29, 2024
pulisher
Oct 26, 2024

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News

Oct 26, 2024
pulisher
Oct 25, 2024

Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News

Oct 25, 2024
pulisher
Oct 25, 2024

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

Oct 25, 2024
pulisher
Oct 25, 2024

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga

Oct 25, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga

Oct 23, 2024
pulisher
Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter

Oct 23, 2024
pulisher
Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Oct 22, 2024

Sangamo Therapeutics Inc Stock (SGMO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):